Eli Lilly Pursues RNA Editing in New Partnership with ProQR

With RNA therapies being the next hot thing in genetic medicine, Eli Lilly is joining the RNA editing race by partnering with Netherlands-based ProQR Therapeutics NV (Nasdaq: PRQR), a biotech company developing RNA-based therapies for rare genetic diseases with a focus on blinding disorders of the retina.

ProQR announced yesterday that it had landed a global licensing and research collaboration with Eli Lilly and Company “focused on the discovery, development and commercialization of potential new medicines for genetic disorders in the liver and nervous system.”